SCHEMBL7195829

SCHEMBL7195829

COP(=O)(OC)c1cc(-c2ccc(C)cc2)ccc1OC(C)CC(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ ALKBH3 Q96Q83 2/20 0.35
▸ PDE4A P27815 3/20 0.32
▸ PDE4B Q07343 3/20 0.32
▸ PDE4C Q08493 3/20 0.32
▸ PDE4D Q08499 3/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ HPGD P15428 2/20 0.32
▸ CTSA P10619 1/20 0.32
▸ CNR1 P21554 3/20 0.31
▸ TAS1R3 Q7RTX0 1/20 0.31
▸ TAS1R1 Q7RTX1 1/20 0.31
▸ FDPS P14324 1/20 0.31
▸ LMNA P02545 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189507 0.86 PDE4A (0.33) GAAPDE4APDE4BPDE4CPDE4D
SCHEMBL7182874 0.82 GAK (0.38) MGAMGAASIMGAM2ALDH1A1
SCHEMBL7527196 0.81 ALDH1A1 (0.43) ALKBH3MEN1KMT2AALDH1A1HPGD
SCHEMBL7597964 0.80 NPC1 (0.33) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL7198638 0.80 ALDH1A1 (0.37) MGAMGAASIMGAM2MEN1
SCHEMBL7188341 0.77 PTPN11 (0.40) GAAMEN1KMT2AALDH1A1LMNA
SCHEMBL7188818 0.75 CFD (0.45) GAAMEN1NPC1KMT2AALDH1A1
SCHEMBL7190202 0.73 TRPA1 (0.40) MGAMGAASIMGAM2PDE4A
SCHEMBL7183095 0.72 MCL1 (0.47) MEN1NPC1KMT2AALDH1A1HPGD
SCHEMBL7600097 0.71 HPRT1 (0.43) ALKBH3MEN1NPC1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 — — EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 — — US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 — — US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO MGAM 1548/4885GAA 252/4885SI 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback